What began as a distant conflict in Middle East could now disrupt something as basic as birth control in India. A string of recent reports says the country’s condom manufacturers are grappling with a severe supply-chain crunch, triggering emerging shortages and the risk of sharp price hikes.
India’s condom market is large and strategically important. It is valued at about ₹860–8,170 crore rupees and produces more than 400 crore condoms every year. State-run HLL Lifecare Ltd alone makes around 221 crore condoms annually, while major private players like Mankind Pharma and Cupid supply both the domestic and export markets.
To keep prices low for a population of 140 crore, the industry runs on a high‑volume, low‑margin model, a structure now being badly shaken, thanks to the American-Israel attacks on Iran that triggered the current Middle East crisis.
What is the Middle East condom connection?
The problem lies in the raw materials. Condom production depends heavily on anhydrous ammonia, used to stabilise natural rubber latex, and silicone oil, used as lubricant. Roughly 86 per cent of India’s anhydrous ammonia imports come from Middle East countries such as Saudi Arabia, Qatar and Oman.
With the Iran-US–Israel conflict disrupting shipping through the Strait of Hormuz, supplies of both ammonia and silicone oil have been choked, pushing up costs and delaying deliveries.
Industry officials told media that there is already a “huge shortage” of silicone oil, while ammonia prices are expected to jump 40–50 per cent, on top of rising costs for PVC foil, aluminium foil and other packaging materials.
Manufacturers reportedly said that production cycles and order execution were being hit, and with ground reports stating “widespread shortages” and an anticipated 50 per cent surge in retail prices if the situation persists.
Disruptions to this ₹8,000‑crore “bedroom economy” could reduce accessibility and threaten family-planning efforts, especially for low‑income users who are most sensitive to price, as per reports.
Public‑health experts have long noted that contraception stock‑outs in low‑income and middle‑income countries can quickly translate into higher rates of unintended pregnancies and sexually transmitted infections when alternatives are unaffordable or unavailable.
India relies on free and subsidised condoms as part of its national family-planning toolkit, and a prolonged squeeze on supplies and higher retail prices would hit both personal wallets and public health.
The latest petrochemicals duty cut is one way the Centre has stepped in, but shipping lanes need to normalise for lasting stability in Indian bedrooms for now.